• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Is tumor microenvironment important for targeted therapy in lung cancer?肿瘤微环境对肺癌的靶向治疗是否重要？
Cancer Lett. 2024 Nov 1;604:217203. doi: 10.1016/j.canlet.2024.217203. Epub 2024 Sep 3.
2
[The targets research of non-small cell lung cancer targeted therapy].[非小细胞肺癌靶向治疗的靶点研究]
Zhongguo Fei Ai Za Zhi. 2013 Feb;16(2):107-13. doi: 10.3779/j.issn.1009-3419.2013.02.09.
3
Immunotherapy in non-small cell lung cancer harbouring driver mutations.携带驱动基因突变的非小细胞肺癌的免疫治疗
Cancer Treat Rev. 2021 May;96:102179. doi: 10.1016/j.ctrv.2021.102179. Epub 2021 Mar 19.
4
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）驱动的肺癌中的程序性死亡受体1（PD-1）轴抑制剂：徒劳无功？
Clin Cancer Res. 2016 Sep 15;22(18):4539-41. doi: 10.1158/1078-0432.CCR-16-1401. Epub 2016 Jul 28.
5
Interleukin-1 in tumor progression, therapy, and prevention.白细胞介素-1 在肿瘤进展、治疗和预防中的作用。
Cancer Cell. 2021 Aug 9;39(8):1023-1027. doi: 10.1016/j.ccell.2021.04.011. Epub 2021 May 13.
6
The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response.肺癌中的代谢重编程及其对治疗反应的潜在影响。
Adv Exp Med Biol. 2020;1219:311-333. doi: 10.1007/978-3-030-34025-4_16.
7
Identification of SMARCAL1 as a molecular target for small cell lung cancer treatment.鉴定SMARCAL1作为小细胞肺癌治疗的分子靶点。
Cancer Lett. 2024 Jun 28;592:216932. doi: 10.1016/j.canlet.2024.216932. Epub 2024 May 11.
8
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.肿瘤固有对 IFNγ 的反应塑造了 NSCLC 的肿瘤微环境和抗 PD-1 反应。
Life Sci Alliance. 2019 May 27;2(3). doi: 10.26508/lsa.201900328. Print 2019 Jun.
9
Therapeutic targeting of TGF-β in lung cancer.肺癌中转化生长因子-β的治疗靶向作用
FEBS J. 2025 Apr;292(7):1520-1557. doi: 10.1111/febs.17234. Epub 2024 Jul 31.
10
Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!为非小细胞肺癌的靶向治疗欢呼三声……当我们命中靶点时！
J Chemother. 2011 Aug;23(4):245-6. doi: 10.1179/joc.2011.23.4.245.

本文引用的文献

1
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect.了解 TKI 诱导的肿瘤免疫微环境变化的动态，以提高治疗效果。
J Immunother Cancer. 2024 Jun 21;12(6):e009165. doi: 10.1136/jitc-2024-009165.
2
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.洛拉替尼治疗初治 ALK 阳性晚期 NSCLC 患者的疗效与 EML4::ALK 变异类型以及 ALK 是否伴有 TP53 突变有关。
J Thorac Oncol. 2023 Nov;18(11):1581-1593. doi: 10.1016/j.jtho.2023.07.023. Epub 2023 Aug 3.
3
Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.关于肿瘤免疫微环境、其异质性以及晚期非小细胞肺癌治疗未来展望的当前文献综述。
Transl Lung Cancer Res. 2023 Apr 28;12(4):857-876. doi: 10.21037/tlcr-22-633. Epub 2023 Mar 17.
4
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法：进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.
5
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.第三代表皮生长因子受体（EGFR）和间变性淋巴瘤激酶（ALK）抑制剂：耐药机制与处理
Nat Rev Clin Oncol. 2022 Aug;19(8):499-514. doi: 10.1038/s41571-022-00639-9. Epub 2022 May 9.
6
Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development.阿司匹林通过抑制KAT5抑制PD-L1表达，随后抑制PD-1和PD-L1信号传导以减弱卵巢癌发展。
J Oncol. 2022 Mar 29;2022:4664651. doi: 10.1155/2022/4664651. eCollection 2022.
7
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review.表皮生长因子受体酪氨酸激酶抑制剂治疗前后表皮生长因子受体突变的非小细胞肺癌中的肿瘤免疫微环境：一篇叙述性综述
Transl Lung Cancer Res. 2021 Sep;10(9):3823-3839. doi: 10.21037/tlcr-21-572.
8
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.膜相关 RING-CH8 作为一种新型的 PD-L1 E3 连接酶，介导 EGFR 抑制剂诱导的 PD-L1 降解。
Mol Cancer Res. 2021 Oct;19(10):1622-1634. doi: 10.1158/1541-7786.MCR-21-0147. Epub 2021 Jun 28.
9
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.在晚期表皮生长因子受体（EGFR）突变的非小细胞肺癌中，阿司匹林与奥希替尼联合使用可提高生存率。
Lung Cancer. 2020 Nov;149:33-40. doi: 10.1016/j.lungcan.2020.08.023. Epub 2020 Sep 9.
10
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.单细胞 RNA 测序揭示人类肺癌的治疗诱导进化。
Cell. 2020 Sep 3;182(5):1232-1251.e22. doi: 10.1016/j.cell.2020.07.017. Epub 2020 Aug 20.

Is tumor microenvironment important for targeted therapy in lung cancer?

作者信息

Sun Shi-Yong

机构信息

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA, USA.

出版信息

Cancer Lett. 2024 Nov 1;604:217203. doi: 10.1016/j.canlet.2024.217203. Epub 2024 Sep 3.

DOI:10.1016/j.canlet.2024.217203
PMID:39236847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11877396/
Abstract
摘要